Literature DB >> 22136157

Thyroid cancer patients treated with 131I: radiation dose to relatives after discharge from the hospital.

Hervé Rémy1, Jérémy Coulot, Isabelle Borget, Marcel Ricard, Nadine Guilabert, Frédéric Lavielle, Eve Camps, Eric Baudin, Jean Lumbroso, Sophie Leboulleux, Martin Schlumberger.   

Abstract

BACKGROUND: Thyroid cancer patients treated with radioiodine are potential source of radiation exposure for other individuals. Thus, we evaluated the radiation dose received by family members of thyroid cancer patients treated with (131)I after hospital discharge.
MATERIALS AND METHODS: Seventy-six family members of 56 thyroid cancer patients were included in the study. Thyroid cancer patients were given 3.7 GBq of (131)I and remained in a radiation protection ward for 3 days. Radiation protection recommendations were given to patients and relatives. Life conditions were recorded and radiation doses were monitored using a personal dosimeter. RESULTS AND DISCUSSION: At discharge, the mean residual activity was 188 MBq. The mean radiation dose delivered to relatives during the 7 days after discharge was low (51.5 μSv) and was similar with either recombinant human thyrotropin (rhTSH) (59 μSv) or withdrawal (50 μSv) (p = 0.37).
CONCLUSION: With our current practice, radiation doses to relatives are low and well below international recommendations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22136157     DOI: 10.1089/thy.2010.0406

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  2 in total

1.  High-Dose Radioiodine Outpatient Treatment: An Initial Experience in Thailand.

Authors:  Danupon Nantajit; Sureerat Saengsuda; Pattama NaNakorn; Yuthana Saengsuda
Journal:  Asia Ocean J Nucl Med Biol       Date:  2015

2.  Higher body weight and distant metastasis are associated with higher radiation exposure to the household environment from patients with thyroid cancer after radioactive iodine therapy.

Authors:  Sheng-Fong Kuo; Tsung-Ying Ho; Miaw-Jene Liou; Kun-Ju Lin; Ru-Chin Cheng; Sheng-Chieh Chan; Bie-Yui Huang; Soh-Ching Ng; Feng-Hsuan Liu; Hung-Yu Chang; Sheng-Hwu Hsieh; Kun-Chun Chiang; Huang-Yang Chen; Ta-You Lo; Chih-Lang Lin; Jen-Der Lin
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.